EE258 Estimating QALY Gains of Oncology Drugs: A Review of Cost-Utility Analysis of Negotiated Drugs in China

Abstract

Authors

L Liu H Xu G Hong Y Jiang J Ming Y Chen

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×